⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ORIC News
Oric Pharmaceuticals, Inc. Common Stock
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
globenewswire.com
ORIC
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
Form 8-K
sec.gov
ORIC
Form 8-K
sec.gov
ORIC
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
ORIC